Current research confirms that this is a promising direction for the development of effective therapies, including the activation of stable forms to activate stable N-heterocyclic carbene-gold(I)-alkyne complexes, transforming them into active species that inhibit thioredoxin reductase and exhibit significant anticancer activity in treating hepatocellular carcinoma [46]. Here, PRDX5 is linked to hepatocellular carcinoma.